Literature DB >> 6391464

Altered blood pressure response to propyldazine after repeated oral administration in conscious normotensive dogs: role of the renin-angiotensin system.

S Bacher, O Kraupp, A Beck, R Seitelberger, G Raberger.   

Abstract

The magnitude and the persistence of blood pressure reduction by propyldazine (PDZ) was investigated following treatment over a period of 4 days. The experiments were performed on 6 normotensive dogs trained to submit to puncture of the femoral artery and to stand quietly in a special frame over the experimental period of 7 to 8 hours. The first dose effect of orally administered PDZ (0.06, 0.29 and 1.42 mg/kg) on heart rate, arterial blood pressure and plasma renin activity (PRA) was compared with the effect of the substance after treatment at the same respective dosage twice daily over 4 days. The compound caused a dose-dependent decrease in blood pressure accompanied by dose-dependent increases in heart rate and PRA. With 0.06 mg/kg and 0.29 mg/kg PDZ a sustained effect on arterial blood pressure was observed, whereas with 1.42 mg/kg PDZ tolerance occurred after treatment over the 4-day period. A comparison with the effects observed previously with 1.42 and 7.1 mg/kg dihydralazine (DHZ) under identical conditions showed similar results with respect to dose-dependence of blood pressure and counterregulation (1). It is considered that with a low-dose regimen there would be no decrease in activity of PDZ, the long-term hypotensive efficacy of the drug thereby being guaranteed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6391464     DOI: 10.1007/BF01910488

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  21 in total

1.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

2.  Blood pressure response and renin release following 4 days of treatment with dihydralazine and urapidil in conscious dogs.

Authors:  S Bacher; O Kraupp; A Beck; R Seitelberger; G Raberger
Journal:  Cardiovasc Res       Date:  1984-02       Impact factor: 10.787

Review 3.  Hydralazine and related compounds: chemistry, metabolism, and mode of action.

Authors:  P A Reece
Journal:  Med Res Rev       Date:  1981       Impact factor: 12.944

4.  Determinants of drug response in severe chronic heart failure. 1. Activation of vasoconstrictor forces during vasodilator therapy.

Authors:  M Packer; J Meller; N Medina; M Yushak; R Gorlin
Journal:  Circulation       Date:  1981-09       Impact factor: 29.690

5.  A new antihypertensive compound: 3 hydrazino-6- [(2-hydroxypropyl)methylamino] pyridazine dihydrochloride (ISF 2123).

Authors:  L Dorigotti; R Rolandi; C Carpi
Journal:  Pharmacol Res Commun       Date:  1976-06

6.  Changes in control of renin release in congestive heart failure in dogs: response to acute and chronic vasodilator therapy.

Authors:  R Engler; H Pouleur; J Link; M Printz; J W Covell
Journal:  Clin Exp Hypertens A       Date:  1982

7.  Plasma noradrenaline as a measure of baroreflex sensitivity in hypertensive man.

Authors:  A M Shepherd; M S Lin; T K Keeton; J L McNay
Journal:  Clin Sci (Lond)       Date:  1981-12       Impact factor: 6.124

8.  Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects.

Authors:  K Chatterjee; T A Ports; B H Brundage; B Massie; A N Holly; W W Parmley
Journal:  Ann Intern Med       Date:  1980-05       Impact factor: 25.391

9.  Renal function studies with propildazine alone and in combination with propranolol in dogs.

Authors:  L Dorigotti; C Semeraro
Journal:  Eur J Pharmacol       Date:  1980-10-17       Impact factor: 4.432

10.  Pharmacokinetics of hydralazine, apparent hydralazine and hydralazine pyruvic acid hydrazone in humans.

Authors:  A M Shepherd; T M Ludden; K D Haegele; T Talseth; J L McNay
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.